scRNAseq of four syngeneic human melanoma cell lines (two replicate per cell line) to study mechanisms of resistance to the BRAF inhibitor vemurafenib
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/ERP143260
下载链接
链接失效反馈官方服务：
资源简介：
Three cell lines were derived from the A375 human melanoma (harbouring the BRAF v600e mutation; ATCC) after treatment with vemurafenib during a period of 4-5 weeks in the absence (MAPKi-resist Rep1/Rep2) or presence of the fatty acid oxidation inhibitors etomoxir (Etomoxir Rep1/Rep2) or ranolazine (Ranolazine Rep1/Rep2).
创建时间：
2023-10-13
